The company specializes in developing small molecule medicines designed to tackle critical gaps in oncology care. Proceeds from the offering are earmarked for the advancement of its clinical pipeline, specifically the lead candidate BH-30643. This drug is currently undergoing a Phase 1/2 study focused on patients with EGFR-mutant non-small cell lung cancer.

While the filing confirms the intent to go public, it stops short of disclosing the volume of shares to be offered or the projected capital raise. Investors are looking to BlossomHill as a fresh entrant in the biopharma space, provided the company successfully navigates the regulatory requirements for its listing on the Nasdaq exchange.